10 newer rulings cite the same tariff codes.
Classification can shift over time. Review the more recent rulings below before relying on this one.
The tariff classification of Dapoxetine tablets from Canada
Issued February 14, 2002 by U.S. Customs and Border Protection.
Cite this ruling
Copies to clipboardH8 H88024 (February 14, 2002)
Tariff classification
HTS codes: 3004.90.9135
Headings: 3004
Product description
The subject product, Dapoxetine tablets, is a medicament containing the active ingredient, Dapoxetine, a serotonin reuptake inhibitor being developed as an investigational drug for the treatment of premature ejaculation. You have indicated to a member of my staff, in a telephone facsimile, dated February 11, 2002, that your client has advised you that the subject product is currently in Phase III clinical trials in the U.S.
CBP rationale
The applicable subheading for Dapoxetine tablets will be 3004.90.9135, Harmonized Tariff Schedule of the United States (HTS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale: Other: Other: Other: Medicaments primarily affecting the central nervous system: Antidepressants, tranquilizers, and other psychotherapeutic agents.
Full text
NY H88024 February 14, 2002 CLA-2-30:RR:NC:2:238 H88024 CATEGORY: Classification TARIFF NO.: 3004.90.9135 Mr. James F. Morgan PBB Global Logistics 883-D Airport Park Road Glen Burnie, MD 21061 RE: The tariff classification of Dapoxetine tablets from Canada Dear Mr. Morgan: In your letter dated January 22, 2002, on behalf of your client, Patheon, you requested a tariff classification ruling. The subject product, Dapoxetine tablets, is a medicament containing the active ingredient, Dapoxetine, a serotonin reuptake inhibitor being developed as an investigational drug for the treatment of premature ejaculation. You have indicated to a member of my staff, in a telephone facsimile, dated February 11, 2002, that your client has advised you that the subject product is currently in Phase III clinical trials in the U.S. The applicable subheading for Dapoxetine tablets will be 3004.90.9135, Harmonized Tariff Schedule of the United States (HTS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale: Other: Other: Other: Medicaments primarily affecting the central nervous system: Antidepressants, tranquilizers, and other psychotherapeutic agents.” The general rate of duty will be free. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 301-443-1544. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Budesonide Capsules from India and Perphenazine Tablets from Italy
The tariff classification of Linezolid tablets and Trazodone Hydrochloride tablets in dosage form, from India
The tariff classification of Aripiprazole Orally Disintegrating Tablets in dosage form, from India
The tariff classification of Bupropion Hydrochloride Extended Release Tablets, imported in dosage form, from India. Correction to Ruling Number N258062.
The tariff classification of Bupropion Hydrochloride Extended Release Tablets, imported in dosage form, from India
The tariff classification of Olanzapine Tablets and Olanzapine Orally Disintegrating Tablets, imported in dosage form, from India
The tariff classification of Duloxetine Hydrochloride Capsules, imported in dosage form, from India
The tariff classification of Duloxetine Delayed Release Capsules, imported in dosage form, from India
The tariff classification of Bupropion Hydrochloride Extended Release Tablets, imported in dosage form, from India
The tariff classification of Duloxetine Hydrochloride Capsules (CAS-136434-34-9), imported in dosage form, from India
Follow H88024
Get an email if this ruling is revoked or modified, or a newer ruling supersedes it.
One email per day at most. Confirm your address once, unsubscribe anytime.
Searching CBP rulings the smart way
Rulings are precedent. See which ones apply to your product: TariffLens semantically searches all 200,000+ CBP rulings and builds defensible classifications backed by ruling citations.